OpenURL Connection Search

Select item for more details and to access through your institution.

'No Child Need Have Rickets' Revisited.
Published in:
Journal of Pediatric Endocrinology & Metabolism, 2008, v. 21, n. 2, p. 107, doi. 10.1515/jpem.2008.21.2.107
By:
- Berry, Tymara;
- Rapaport, Robert
Publication type:
Article
Fedratinib Induces Spleen Responses and Reduces Symptom Burden as First-line or Salvage Therapy in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) and Low Platelet Counts.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S355, doi. 10.1016/j.clml.2019.07.374
By:
- Harrison, Claire;
- Schaap, Nicolaas;
- Vannucchi, Alessandro;
- Kiladjian, Jean-Jacques;
- Passamonti, Francesco;
- Zweegman, Sonja;
- Talpaz, Moshe;
- Verstovsek, Srdan;
- Gerike, Torsten;
- Rose, Shelonitda;
- Zhang, Jun;
- Berry, Tymara;
- Brownstein, Carrie;
- Mesa, Ruben
Publication type:
Article
Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm (MPN)-Associated Intermediate- or High-Risk Myelofibrosis (MF) Resistant or Intolerant to Ruxolitinib: An Updated Analysis of the Phase II JAKARTA2 Study.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S356, doi. 10.1016/j.clml.2019.07.375
By:
- Harrison, Claire;
- Schaap, Nicolaas;
- Vannucchi, Alessandro;
- Kiladjian, Jean-Jacques;
- Jourdan, Eric;
- Silver, Richard;
- Schouten, Harry;
- Passamonti, Francesco;
- Zweegman, Sonja;
- Talpaz, Moshe;
- Verstovsek, Srdan;
- Gerike, Torsten;
- Rose, Shelonitda;
- Li, Mingyu;
- Berry, Tymara;
- Brownstein, Carrie;
- Mesa, Ruben
Publication type:
Article
Population pharmacokinetics of imetelstat, a first‐in‐class oligonucleotide telomerase inhibitor.
Published in:
CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 7, p. 1264, doi. 10.1002/psp4.13160
By:
- González‐Sales, Mario;
- Lennox, Ashley L.;
- Huang, Fei;
- Pamulapati, Chandra;
- Wan, Ying;
- Sun, Libo;
- Berry, Tymara;
- Kelly Behrs, Melissa;
- Feller, Faye;
- Morcos, Peter N.
Publication type:
Article
nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC.
Published in:
Frontiers in Oncology, 2018, p. N.PAG, doi. 10.3389/fonc.2018.00262
By:
- Langer, Corey J.;
- Kim, Edward S.;
- Anderson, Eric C.;
- Jotte, Robert M.;
- Modiano, Manuel;
- Haggstrom, Daniel E.;
- Socoteanu, Matei P.;
- Smith, David A.;
- Dakhil, Christopher;
- Konduri, Kartik;
- Berry, Tymara;
- Ong, Teng J.;
- Sanford, Alexandra;
- Amiri, Katayoun;
- Goldman, Jonathan W.;
- Weiss, Jared;
- on behalf of the ABOUND.70+ Investigators;
- Gajra;
- Dobrescu;
- Halibey
Publication type:
Article
nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2.
Published in:
Frontiers in Oncology, 2018, p. N.PAG, doi. 10.3389/fonc.2018.00253
By:
- Gajra, Ajeet;
- Karim, Nagla Abdel;
- Mulford, Deborah A.;
- Villaruz, Liza Cosca;
- Matrana, Marc Ryan;
- Ali, Haythem Y.;
- Santos, Edgardo S.;
- Berry, Tymara;
- Ong, Teng Jin;
- Sanford, Alexandra;
- Amiri, Katayoun;
- Spigel, David R.
Publication type:
Article
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
Published in:
American Journal of Hematology, 2020, v. 95, n. 6, p. 594, doi. 10.1002/ajh.25777
By:
- Harrison, Claire N.;
- Schaap, Nicolaas;
- Vannucchi, Alessandro M.;
- Kiladjian, Jean‐Jacques;
- Jourdan, Eric;
- Silver, Richard T.;
- Schouten, Harry C.;
- Passamonti, Francesco;
- Zweegman, Sonja;
- Talpaz, Moshe;
- Verstovsek, Srdan;
- Rose, Shelonitda;
- Shen, Juan;
- Berry, Tymara;
- Brownstein, Carrie;
- Mesa, Ruben A.
Publication type:
Article

Found: 7

'No Child Need Have Rickets' Revisited.

Fedratinib Induces Spleen Responses and Reduces Symptom Burden as First-line or Salvage Therapy in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) and Low Platelet Counts.

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm (MPN)-Associated Intermediate- or High-Risk Myelofibrosis (MF) Resistant or Intolerant to Ruxolitinib: An Updated Analysis of the Phase II JAKARTA2 Study.

Population pharmacokinetics of imetelstat, a first‐in‐class oligonucleotide telomerase inhibitor.

nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC.

nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2.

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.